Soligenix
SNGX · Nasdaq · United States
Share price · SNGX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when SNGX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 18 Nov 2026-9.9%
Nothing announced by SNGX that day or the session before.
- 16 Nov 2026-10.2%
Nothing announced by SNGX that day or the session before.
- 3 Jun 2026-36.0%
Nothing announced by SNGX that day or the session before.
- 27 May 2026+70.6%
- 26 May 2026+30.8%
- 28 Apr 2026-70.4%
- 20 Apr 2026+10.4%
Nothing announced by SNGX that day or the session before.
- 17 Dec 2025-19.1%
Share of unusual movement by asset
For each asset, the share of SNGX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Photosensitizer (visible-light activated)Small molecule | Indication not yet linked |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $0.4M | $9.0M | $1.1M-$1.4M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $1.0M | $9.8M | $2.0M-$1.7M operating cash flow | report ↗ |
| 2026-Q1 | $0 | $1.8M | $6.0M | $2.8M | report ↗ |
| 2025-Q3 | — | $1.6M | $11M | $2.5M-$2.9M operating cash flow | report ↗ |
| 2025-Q2 | — | $1.7M | $5.1M | $2.7M-$2.7M operating cash flow | report ↗ |
| 2025-Q1 | — | $2.2M | $7.3M | $3.2M-$1.9M operating cash flow | report ↗ |
| 2024-Q3 | — | $1.0M | $9.8M | $1.7M-$2.9M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $0.5M | $9.4M | $1.6M-$1.9M operating cash flow | report ↗ |
| 2024-Q1 | $0.1M | $1.1M | $7.1M | $1.9M-$1.3M operating cash flow | report ↗ |
| 2023-Q3 | $0.1M | $0.8M | $10M | $1.7M-$2.7M operating cash flow | report ↗ |
| 2023-Q2 | $0.2M | $0.8M | $13M | $1.6M-$1.9M operating cash flow | report ↗ |
| 2023-Q1 | $0.3M | $0.9M | $10M | $1.1M-$2.2M operating cash flow | report ↗ |
| 2022-Q3 | $0.2M | $1.8M | $17M | $3.3M-$3.3M operating cash flow | report ↗ |
| 2022-Q2 | $0.2M | $2.0M | $20M | $2.4M-$2.5M operating cash flow | report ↗ |
| 2022-Q1 | $0.2M | $1.8M | $23M | $4.3M-$3.2M operating cash flow | report ↗ |
| 2021-Q3 | $0.2M | $2.5M | $29M | $3.6M-$3.0M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $7.5M | $7.9M | $2.8M-$10M operating cash flow | report ↗ |
Soligenix reported revenue was not disclosed for fiscal 2025 (prior-year revenue was $0.12M), with R&D spend of $7.49M, up 43.5% YoY. Cash and equivalents totaled $7.94M, and the company reported a net loss of $11.08M, with quarterly net burn of $11.08M. No analyst expectations were provided in the material.
No financial guidance was provided. Soligenix continued advancing its confirmatory Phase 3 FLASH2 trial of HyBryte for cutaneous T-cell lymphoma, having completed enrollment of 50 patients for the planned Q2 2026 interim analysis, with top-line results expected in the second half of 2026; the first Data Monitoring Committee meeting reported no safety concerns. The company also completed the transfer of synthetic hypericin manufacturing to Sterling Pharma Solutions under its partnership agreement, while SGX302 for psoriasis remains in an ongoing Phase 2a study, SGX945 for Behçet’s disease completed its Phase 2a study, and SGX942 for oral mucositis continues to await a partnership for further development.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $0.1M | $5.2M | $7.8M | $2.1M-$8.4M operating cash flow | report ↗ |
| 2023-FY | $0.8M | $3.3M | $8.4M | $1.5M-$8.6M operating cash flow | report ↗ |
| 2022-FY | $0.9M | $7.9M | $13M | $3.5M-$13M operating cash flow | report ↗ |
| 2021-FY | $0.8M | $8.4M | $26M | $3.1M-$12M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-12 | SCHABER CHRISTOPHER J · director, CHAIRMAN, CEO AND PRESIDENT | Disposition to issuer (derivative) | 250 | — | — | Form 4 |
| 2026-10-12 | Guarino Jonathan L. · CFO | Disposition to issuer (derivative) | 166 | — | — | Form 4 |
| 2026-10-12 | Donini Oreola · CSO | Disposition to issuer (derivative) | 83 | — | — | Form 4 |
| 2026-10-12 | LAPOINTE ANTHONY GREGG · director | Disposition to issuer (derivative) | 54 | — | — | Form 4 |
| 2026-10-12 | Parks Diane L. · director | Disposition to issuer (derivative) | 6 | — | — | Form 4 |
| 2026-10-12 | RUBIN ROBERT J. · director | Disposition to issuer (derivative) | 54 | — | — | Form 4 |
| 2026-10-12 | ZELDIS JEROME B · director | Disposition to issuer (derivative) | 54 | — | — | Form 4 |
| 2026-10-12 | SCHABER CHRISTOPHER J · director, CHAIRMAN, CEO AND PRESIDENT | Disposition to issuer (derivative) | 250 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 15 reporting institutions held 0.3M shares ($307K, 1.1% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT, LLC | 120,267 | $142K |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 58,400 | $69K |
| 3 | VANGUARD FIDUCIARY TRUST CO | 53,914 | $64K |
| 4 | XTX Topco Ltd | 20,799 | $25K |
| 5 | MORGAN STANLEY | 3,592 | $4K |
| 6 | UBS Group AG | 2,346 | $3K |
| 7 | SBI Securities Co., Ltd. | 402 | $474 |
| 8 | JPMORGAN CHASE & CO | 305 | $338 |
| 9 | Advisory Services Network, LLC | 209 | $247 |
| 10 | Plante Moran Financial Advisors, LLC | 209 | $247 |
| 11 | JONES FINANCIAL COMPANIES LLLP | 100 | $113 |
| 12 | CITIGROUP INC | 19 | $22 |
| 13 | CWM, LLC | 6 | $7 |
| 14 | OSAIC HOLDINGS, INC. | 2 | $2 |
| 15 | ALBION FINANCIAL GROUP /UT | 1 | $2 |